Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × exemestane × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 25 Neoplasms 4 Carcinoma, Intraductal, Noninfiltrating 3 Ovarian Neoplasms 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Tuberous Sclerosis 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Locoregional Recurrence 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 Granulosa cell tumor of the ovary 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Anatomic Stage III Breast Cancer AJCC v8 1 Advanced Breast Carcinoma 1 Acrocephalosyndactylia 1

Interventions

Fulvestrant 2 trastuzumab deruxtecan 1 ribociclib 1 exemestane 1 Tamoxifen 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡